106 related articles for article (PubMed ID: 26562476)
1. Disease kinetics but not disease burden is relevant for survival in melanoma of unknown primary tumor.
Heppt MV; Tietze JK; Reinholz M; Rahimi F; Jung A; Kirchner T; Ruzicka T; Flaig MJ; Berking C
Discov Med; 2015 Oct; 20(110):231-7. PubMed ID: 26562476
[TBL] [Abstract][Full Text] [Related]
2. Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.
Egberts F; Bergner I; Krüger S; Haag J; Behrens HM; Hauschild A; Röcken C
Ann Oncol; 2014 Jan; 25(1):246-50. PubMed ID: 24276025
[TBL] [Abstract][Full Text] [Related]
3. Melanoma of unknown primary origin: a population-based study in the Netherlands.
de Waal AC; Aben KK; van Rossum MM; Kiemeney LA
Eur J Cancer; 2013 Feb; 49(3):676-83. PubMed ID: 23031553
[TBL] [Abstract][Full Text] [Related]
4. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma.
Lee CC; Faries MB; Wanek LA; Morton DL
J Clin Oncol; 2008 Feb; 26(4):535-41. PubMed ID: 18235114
[TBL] [Abstract][Full Text] [Related]
5. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
6. Metastatic melanoma to lymph nodes in patients with unknown primary sites.
Cormier JN; Xing Y; Feng L; Huang X; Davidson L; Gershenwald JE; Lee JE; Mansfield PF; Ross MI
Cancer; 2006 May; 106(9):2012-20. PubMed ID: 16568458
[TBL] [Abstract][Full Text] [Related]
7. Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease.
van der Ploeg AP; Haydu LE; Spillane AJ; Scolyer RA; Quinn MJ; Saw RP; Shannon KF; Stretch JR; Thompson JF
Ann Surg Oncol; 2014 Sep; 21(9):3108-16. PubMed ID: 24802907
[TBL] [Abstract][Full Text] [Related]
8. Melanomas of unknown primary frequently harbor TERT-promoter mutations.
Egberts F; Krüger S; Behrens HM; Bergner I; Papaspyrou G; Werner JA; Alkatout I; Haag J; Hauschild A; Röcken C
Melanoma Res; 2014 Apr; 24(2):131-6. PubMed ID: 24463461
[TBL] [Abstract][Full Text] [Related]
9. Improved survival for stage IV melanoma from an unknown primary site.
Lee CC; Faries MB; Wanek LA; Morton DL
J Clin Oncol; 2009 Jul; 27(21):3489-95. PubMed ID: 19451446
[TBL] [Abstract][Full Text] [Related]
10. Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis.
Ludwig SV; F Cheng P; Mangana J; Braun R; Dummer R; Koelblinger P
Eur J Dermatol; 2020 Dec; 30(6):699-709. PubMed ID: 33459260
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
12. Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.
Dutton-Regester K; Kakavand H; Aoude LG; Stark MS; Gartside MG; Johansson P; O'Connor L; Lanagan C; Tembe V; Pupo GM; Haydu LE; Schmidt CW; Mann GJ; Thompson JF; Scolyer RA; Hayward NK
Pigment Cell Melanoma Res; 2013 Nov; 26(6):852-60. PubMed ID: 23890154
[TBL] [Abstract][Full Text] [Related]
13. Survival after lymphadenectomy of nodal metastases from melanoma of unknown primary site.
Gullestad HP; Ryder T; Goscinski M
J Plast Surg Hand Surg; 2023; 57(1-6):109-114. PubMed ID: 34878354
[TBL] [Abstract][Full Text] [Related]
14. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
16. Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014.
Scott JF; Conic RZ; Thompson CL; Gerstenblith MR; Bordeaux JS
J Am Acad Dermatol; 2018 Aug; 79(2):258-265.e4. PubMed ID: 29580859
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
[TBL] [Abstract][Full Text] [Related]
18. Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009.
Pfeil AF; Leiter U; Buettner PG; Eigentler TK; Weide B; Meier F; Garbe C
Melanoma Res; 2011 Jun; 21(3):228-34. PubMed ID: 21502902
[TBL] [Abstract][Full Text] [Related]
19. Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome.
Hughes MC; Wright A; Barbour A; Thomas J; Smithers BM; Green AC; Khosrotehrani K
Int J Cancer; 2013 Dec; 133(12):3000-7. PubMed ID: 23754707
[TBL] [Abstract][Full Text] [Related]
20. Solitary melanoma confined to the dermal and/or subcutaneous tissue: evidence for revisiting the staging classification.
Bowen GM; Chang AE; Lowe L; Hamilton T; Patel R; Johnson TM
Arch Dermatol; 2000 Nov; 136(11):1397-9. PubMed ID: 11074704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
